top of page
Pharma Weekly Report
Biotech news this week — what actually mattered Big pharma is buying innovation again Merck in talks to acquire Revolution Medicines Merck is reportedly in advanced discussions to acquire Revolution Medicines in a deal valued as high as $32 billion. Revolution focuses on precision cancer drugs targeting difficult mutations, including RAS-driven tumors that have historically been hard to treat. Why this matters: This shows that large pharma companies are willing to pay a premi
8 min read
Healthcare Services and Disease Report
Latest Worldwide Advances in Disease Care Services, First Week of January 2026 Introduction The global landscape of disease care services in January 2026 is defined by a definitive inflection point known as the "Great Divergence." This period marks a fracture in the global consensus on healthcare delivery, driven by disparate economic pressures and epidemiological realities. In the United States, the sector is dominated by a radical fiscal contraction following the operatio
22 min read
Consumer Non Durable Report
Introduction Building on last week’s theme of operational efficiency under consumer pressure , this week’s signal is control and consolidation . Across consumer non-durables and entertainment, companies are responding to: Cautious consumers Platform dominance Subscription fatigue Margin pressure by consolidating offerings, tightening control over access, and monetising attention more precisely . The big shift this week is not about creating more choice — it is about controlli
4 min read
bottom of page